tbuckley/cabot-search huggingface dataset:
Myanmar doctors are under fire from the military and covid-19
Authors: Geetanjali Krishna, Sally Howard
Journal: BMJ (2021)

Even in a country with a history of politicising healthcare, the six months since the Tatmadaw armed forces seized power in Myanmar on 1 February have been particularly bloody for the nation's healthcare professionals.On 28 March, during a strike against the military dictatorship in the city of Monywa, a nurse was fatally shot in the head.On 21 April, two private hospitals in Bhamo, Kachin state, had their licences to treat patients revoked.This came after Myanmar armed forces said they would revoke the licence of any health facility that employs health workers who participate in the civil disobedience movement resisting the junta's rule, and would prosecute those that provide assistance to health workers.On 8 May, in northern Kachin, a doctor was arrested and fatally shot in the head while passing a military base, and in June, two covid-19 treatment centres in Sagaing were destroyed by military shelling.In this, the third military coup in the last 60 years, Myanmar has become one of the most dangerous places on earth for healthcare workers, with 240 attacks this year; nearly half of the 508 attacks tracked globally by the World Health Organization.A report in July by UK Aid, USAID, and Manchester University's Researching the Impact of Attacks on Healthcare 1 found that there had been 190 arrests of healthcare workers, 25 killings of healthcare workers, and 55 military occupations of hospitals in the five months to 1 July. FEATURE
Abstract 4566: Growth and Function of Hypoplastic Right Ventricles and Tricuspid Valves in Infants with Pulmonary Atresia and Intact Ventricular Septum
Authors: John E Foker, James M Berry, Shaun Setty, Andrew Rivard, Adriana C Gittenberger-de Groot, Lee A Pyles
Journal: Circulation (2008)

Objectives The pulmonary atresia intact septum (PAIVS) spectrum includes very hypoplastic right ventricles (RVs) and tricuspid valves (TVs) as well as RV-coronary artery connections (RV-CACs). These abnormalities are often thought irreversible and only 30 – 40% reach a 2-ventricle repair (2VR). Our hypothesis, however, has been PAIVS is a developmental defect and catch-up growth is possible. We provide up to 10 year data on RV and TV growth and function after 2VR. Methods Follow-up echo data were sought on the 24 survivors of the 28 patients (pts) treated from 1989 –1999. Two pts with Ebstein’s anomaly and one without coronary-aorta connections were excluded. Biplane echos were required for accurately estimating RV volume, TV size, and function. Measurements were indexed (I) to determine the z-values (standard deviation of the mean from predicted). Results All patients had an RV outflow patch and ASD reduction. Growth required complete relief of RV obstruction and a mildly restrictive (3–5 mmHg) ASD to encourage TV flow. A central shunt was placed in 38%. RV-CACs (2.7 ± 1.6/pt) were uneventfully ligated off bypass in 9/28 (32%). For the 24 survivors, 19 adequate paired biplane studies were obtained and 12 approached 10 year follow-up. No central shunts remained. The other survivors were satisfactory on local follow-up visits. The TVs, despite increased flow, grew more slowly than RVs. But even very small TVs in 10 pts went from z-values of −4.6 ± 0.4 to −0.04 ± −1.5 within 5–10 years. Normal size was achieved in 9/10 and 1 went from z = −5.2 to −3.1. Valvotomies were done in 3. RV function was high normal (EF = 74.5 ± 0.1%) because of pulmonary regurgitation in 8 pts with adequate studies. Conclusions 1) Catch-up growth appears reliable in PAIVS pts even for TV z-values ≤ −4.0. 2) The consequences of PAIVS can be reversed by growth when RV obstruction is relieved and TV flow increased. 3) RV function was good and resembled well repaired TOF. 4) These results encourage pursuing 2VRs in PAIVS pts. Paired follow-up z-values and indexed sizes for the RVs and TVs
Unraveling the mechanisms of IVIG immunotherapy in MIS-C
Authors: Madhusudan Ganigara, Chetan Sharma, Jagadeesh Bayry
Journal: Cell Reports Medicine (2021)

In The Journal of Clinical Investigation, Zhu et al.1 report that intravenous immunoglobulin (IVIG) targets IL-1β+ neutrophils to exert anti-inflammatory effects in multisystem inflammatory syndrome in children (MIS-C), a post-infectious inflammatory condition associated with COVID-19.
1048P Baseline and post-treatment biomarkers of resistance to anti-PD-1 (aPD1) therapy in acral and mucosal melanoma
Authors: J. Lee, X.Q. Liu, Q. Zhao, K-M. Kim, S.T. Kim, Y. Sun, J. Yearley, T. Choudhury, A. Webber, C. Krepler, R. Cristescu, I. Shui
Journal: Annals of Oncology (2021)
1692P Thromboprophylaxis in high-risk oncology patients: Is it a safe and effective clinical decision-intervention?
Authors: N.G. Tsoukalas, A.N. Christopoulou, E. Timotheadou, A. Koumarianou, I. Athanasiadis, S. Peroukidis, G.F. Samelis, A. Psyrri, N. Kapodistrias, A. Nikolakopoulos, S. Demiri, C. Andreadis, A. Ardavanis, I. Sgouros, A. Bokas, V. Barbounis, N. Kentepozidis, D. Mavroudis, P. Papakotoulas, I. Boukovinas
Journal: Annals of Oncology (2021)
1074P Italian nivolumab Expanded Access Program (EAP) in melanoma adjuvant setting: Patients outcomes and safety profile
Authors: M. Del Vecchio, A.M. Di Giacomo, P. Quaglino, V. Chiarion Sileni, P. Queirolo, F. De Galitiis, F. Cognetti, M. Mandala', M. Guidoboni, G. Rinaldi, R. Depenni, F. Consoli, T. Troiani, M. Guida, R. Marconcini, P.F. Ferrucci, M. Bersanelli, None E. rossi, M. Aglietta, P.A. Ascierto
Journal: Annals of Oncology (2021)
718TiP KEYNOTE-676 cohort B: Randomized comparator-controlled cohort to evaluate efficacy and safety of pembrolizumab (pembro) plus bacillus Calmette-Guérin (BCG) in patients with high-risk BCG treatment-naive non-muscle invasive bladder cancer (HR NMIBC)
Authors: S.F. Shariat, G. Steinberg, A.M. Kamat, N.D. Shore, S. Alanee, H. Nishiyama, K. Nam, J.L. Godwin, E. Kapadia, N. Hahn
Journal: Annals of Oncology (2021)
1740P Track and treat in NSCLC (TATIN) - ctDNA guided treatment of early resistance to second-line osimertinib treatment in patients with EGFR mutation positive (EGFRm) NSCLC
Authors: M. Jebbink, J.W.T. van der Wel, D. van den Broek, M.C. Boelens, K. Monkhorst, G. Ruiter, S. Burgers, L. Steinbusch, P. Baas, L. Kastelijn, E.E. van der Wall, M. Stellingwerf, E.F.F. Smit, A.J. de Langen
Journal: Annals of Oncology (2021)
1228P Real-world treatment patterns and clinical outcomes in patients from Central Eastern Europe with EGFR-mutated advanced non-small cell lung cancer: Results from a large retrospective study (REFLECT)
Authors: A. Pluzanski, I. Shterev Donev, B. Gafton, U. Janzic, D. Vidovic, R. Lupu, G. Teodorescu, T-E. Ciuleanu
Journal: Annals of Oncology (2021)
Associations Between Historically Redlined Districts and Racial Disparities in Current Obstetric Outcomes
Authors: Stefanie J. Hollenbach, Loralei L. Thornburg, J. Christopher Glantz, Elaine Hill
Journal: JAMA Network Open (2021)

<h3>Importance</h3> Despite much higher health care expenditure than comparable countries, striking racial and ethnic disparities exist in obstetric outcomes in the United States. A multifaceted exploration of the factors influencing these disparities, including the legacy of structural racism, is important to improve health outcomes for all. <h3>Objective</h3> To characterize the association of the historic racially discriminatory home loan practice of redlining with disparities in modern obstetric outcomes. <h3>Design, Setting, and Participants</h3> In this retrospective cohort study of a 9-county birth certificate database in the Finger Lakes region of New York state from 2005 to 2018, modern obstetric outcomes were matched with regions classified by the federal government for mortgage loan servicing based on racially discriminatory criteria from the 1940 Home Owners’ Loan Corporation map (HOLC; also known as<i>the redline map</i>). Patients with a live birth recorded in the data system with a recorded home zip code within the historic HOLC categories were included. Data were analyzed from July to December 2019. <h3>Exposure</h3> Regions previously categorized by historic, racially discriminatory criteria. <h3>Main Outcomes and Measures</h3> Each HOLC area was analyzed for the primary outcome of preterm birth and secondary outcomes of obstetric and medical complications, with logistic regression to address regional and patient-level covariates. <h3>Results</h3> From 2005 until 2018, there were 64 804 live births within the 15 zip codes overlaying historic HOLC regions. Prevalence of preterm birth increased with decreasing HOLC categories, from the lowest overall preterm birth rate of 217 of 2873 births (7.55%) in the zip code historically defined as “Best” or “Still Desirable” and the highest overall preterm birth rate of 427 of 3449 births (12.38%) in the zip code historically defined as “Hazardous.” These associations with preterm birth remained significant in logistic regression controlling for poverty levels and educational attainment (adjusted odds ratio, 1.46; 95% CI, 1.08-1.97) and parental race (adjusted odds ratio, 1.38; 95% CI, 1.25-1.53). <h3>Conclusions and Relevance</h3> In this cohort study, the linkage of historic and modern community data sets with an obstetric data set offered the opportunity to characterize modern obstetric disparities associated with a system of historic inequity. The persistence of these findings after correcting for contemporary community socioeconomic characteristics suggest potential influences of a system of profound structural inequity that ripple forward in time, with impacts that extend beyond measurable socioeconomic inequity.
Tofacitinib reduced death or respiratory failure at 28 d in patients hospitalized with COVID-19 pneumonia
Authors: Steven Y.C. Tong, Neta Petersiel
Journal: Annals of Internal Medicine (2021)

Source CitationGuimarães PO, Quirk D, Furtado RH, et al. Tofacitinib in patients hospitalized with Covid-19 pneumonia. N Engl J Med. 2021;385:406-15. https://pubmed.ncbi.nlm.nih.gov/34133856/AbstractClinical Impact RatingsHospitalists: Infectious Disease: Critical Care: Pulmonology:
315P Treatment patterns in black and indigenous people and people of color (BIPOC) receiving palbociclib for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in a real-world setting: POLARIS study results
Authors: G. Rocque, J. Blum, A. Montero, S. Sonnier, S. McCune, C. Gallagher, T. Pluard, J. Cappelleri, M. Drucker, Y. Wang, D. Tripathy
Journal: Annals of Oncology (2021)
Menopausal hormone therapy and risk of biliary tract cancers
Authors: Sarah S. Jackson, Ruth M. Pfeiffer, Chiara Gabbi, Lesley Anderson, Shahinaz M. Gadalla, Jill Koshiol
Journal: Hepatology (2021)

Gallbladder cancer (GBC) has a female predominance, whereas the other biliary tract cancers (BTCs) have a male predominance, suggesting that sex hormones may be involved in carcinogenesis. We sought to evaluate the association between menopausal hormone therapy (MHT) and the risk of BTC in women.This nested case-control study was conducted in the UK Clinical Practice Research Datalink. Cases diagnosed between 1990 and 2017 with incident primary cancers of the gallbladder (GBC), cholangiocarcinoma (CCA), ampulla of Vater (AVC), and mixed type were matched to 5 controls on birth year, diagnosis year, and years in the general practice using incidence density sampling. Conditional logistic regression was used to calculate ORs and 95% CIs for associations between MHT use and BTC type. The sample consisted of 1,682 BTC cases (483 GBC, 870 CCA, 105 AVC, and 224 mixed) and 8,419 matched controls with a mean age of 73 (SD, 11) years. Combined formulations (estrogen-progesterone) were associated with an increased GBC risk (OR, 1.97; 95% CI, 1.08, 3.59). Orally administered MHT was associated with an increased GBC risk (OR, 2.28; 95% CI, 1.24, 4.17). Estrogen-only formulations (OR, 0.59; 95% CI, 0.34, 0.93) and cream or suppository administrations (OR, 0.57; 95% CI, 0.34, 0.95) were associated with decreased CCA risk. The number of prescriptions, dose, duration of use, and time since last use were not associated with GBC or CCA risk. MHT use was not associated with risk of AVC or mixed cancer.Combination MHT formulations and oral administrations were associated with increased GBC risk, whereas estrogen-only formulations were associated with a lower CCA risk. MHT formulation and administration should be carefully considered when prescribing.
1362TiP Capmatinib versus docetaxel in pretreated patients with MET exon 14 skipping-mutated locally advanced or metastatic NSCLC: The GeoMETry-III phase III study
Authors: P-J. Souquet, S-W. Kim, B. Solomon, J.F. Vansteenkiste, M. Carbini, A. Jary, S. Glaser, A. Chassot Agostinho, J. Wolf
Journal: Annals of Oncology (2021)
1292P Two single-arm, multicenter phase-II trials of PD-1 inhibitors in patients with pulmonary sarcomatoid carcinoma (NCCH1603/NCCH1703)
Authors: R. Toyozawa, K. Itahashi, Y. Goto, Y. Fujiwara, Y. Okuma, T. Kurata, T. Yokoyama, H. Nokihara, T. Yokoi, T. Yamaguchi, Y. Shiraishi, M. Takeda, T. Tokito, A. Nakamura, Y. Hosomi, Y. Ohe
Journal: Annals of Oncology (2021)
Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension
Authors: Mark Toshner, Colin Church, Lars Harbaum, Christopher Rhodes, Sofia S. Villar Moreschi, James Liley, Rowena Jones, Amit Arora, Ken Batai, Ankit A. Desai, John G. Coghlan, J. Simon R. Gibbs, Dee Gor, Stefan Gräf, Louise Harlow, Jules Hernandez-Sanchez, Luke S. Howard, Marc Humbert, Jason Karnes, David G. Kiely, Rick Kittles, Emily Knightbridge, Brian Lam, Katie A. Lutz, William C. Nichols, Michael W. Pauciulo, Joanna Pepke-Zaba, Jay Suntharalingam, Florent Soubrier, Richard C. Trembath, Tae-Hwi L. Schwantes-An, S. John Wort, Martin R. Wilkins, Sean Gaine, Nicholas W. Morrell, Paul A. Corris
Journal: European Respiratory Journal (2021)

Background Inflammation and dysregulated immunity are important in the development of pulmonary arterial hypertension (PAH). Compelling preclinical data supports the therapeutic blockade of interleukin-6 (IL-6) signalling. Methods We conducted a phase 2 open-label study of intravenous tocilizumab (8 mg·kg −1 ) over 6 months in patients with group 1 PAH. Co-primary end-points were safety, defined by incidence and severity of adverse events, and change in pulmonary vascular resistance. Separately, a mendelian randomisation study was undertaken on 11 744 individuals with European ancestry including 2085 patients with idiopathic/heritable disease for the IL-6 receptor ( IL6R ) variant (rs7529229), known to associate with circulating IL-6R levels. Results We recruited 29 patients (male/female 10/19; mean± sd age 54.9±11.4 years). Of these, 19 had heritable/idiopathic PAH and 10 had connective tissue disease-associated PAH. Six were withdrawn prior to drug administration; 23 patients received at least one dose of tocilizumab. Tocilizumab was discontinued in four patients owing to serious adverse events. There were no deaths. Despite evidence of target engagement in plasma IL-6 and C-reactive protein levels, both intention-to-treat and modified intention-to-treat analyses demonstrated no change in pulmonary vascular resistance. Inflammatory markers did not predict treatment response. Mendelian randomisation did not support an effect of the lead IL6R variant on risk of PAH (OR 0.99, p=0.88). Conclusion Adverse events were consistent with the known safety profile of tocilizumab. Tocilizumab did not show any consistent treatment effect.
Why we don't move: The importance of somatic maintenance and resting
Authors: Joshua M. Schrock
Journal: Behavioral and Brain Sciences (2021)

Abstract A compelling ecological theory of movement and vigor must explain why humans and other animals spend so much time not moving. When we rest, our somatic maintenance systems continue to work. When our somatic maintenance requirements increase, we place greater subjective value on resting. To explain variation in movement and vigor, we must account for the subjective value of resting.
161P Population effectiveness model of the consequences of recurrence after trastuzumab emtansine (T-DM1) treatment among U.S. patients with high-risk HER2+ early-stage breast cancer (ESBC)
Authors: D.L. Veenstra, N. Hendrix, C.M. Dolan, K.A. Fisher, D. Lalla, N. Oestreicher, B. Moy
Journal: Annals of Oncology (2021)
Psychiatrists Explore Legacy of Traumatic Stress in Early Life
Authors: Lynne Lamberg
Journal: JAMA (2001)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
162P Prevalence and spectrum analysis of germline BRCA1 and BRCA2 variants of unclear significance in HBOC Syndrome: Decoding the mysterious signals of the genome
Authors: A. Fiorino, D. Fanale, L. Incorvaia, N. Barraco, M. Bono, C. Brando, K.M. Calcara, V. Calò, D. Cancelliere, A. Dimino, C. Filorizzo, M. Greco, L. Magrin, E. Pedone, A. Perez, A. Pivetti, S. Sammataro, R. Sciacchitano, V. Bazan, A. Russo
Journal: Annals of Oncology (2021)
COVID-19 vaccination in Sindh Province, Pakistan: A modelling study of health impact and cost-effectiveness
Authors: Carl A. B. Pearson, Fiammetta Bozzani, Simon R. Procter, Nicholas G. Davies, Maryam Huda, Henning Tarp Jensen, Marcus Keogh-Brown, Muhammad Khalid, Sedona Sweeney, Sergio Torres-Rueda, Rosalind M. Eggo, Anna Vassall, Mark Jit
Journal: PLoS Medicine (2021)

Multiple Coronavirus Disease 2019 (COVID-19) vaccines appear to be safe and efficacious, but only high-income countries have the resources to procure sufficient vaccine doses for most of their eligible populations. The World Health Organization has published guidelines for vaccine prioritisation, but most vaccine impact projections have focused on high-income countries, and few incorporate economic considerations. To address this evidence gap, we projected the health and economic impact of different vaccination scenarios in Sindh Province, Pakistan (population: 48 million).
458P Circulating tumor DNA analysis predicting recurrence risk in patients with stage I-III colorectal cancer
Authors: J. Gu, F. Lei, X. Wang, W. Huang, X. He, Y. Hong, Q. Zeng, Y. Wang, Q. Gao, P. Niu, D. Huang, Z. Gao, C. Ding, Z. Zhai, K. An, H. Chen, X. Zhao, S. Chen, Y. Bai
Journal: Annals of Oncology (2021)
Phase I/Ib Study of the Efficacy and Safety of Buparlisib and Ibrutinib Therapy in MCL, FL, and DLBCL with Serial Cell-Free DNA Monitoring
Authors: Caitlin M. Stewart, Laure Michaud, Karissa Whiting, Reiko Nakajima, Chelsea Nichols, Stephanie De Frank, Paul A. Hamlin, Matthew J. Matasar, John F. Gerecitano, Pamela Drullinsky, Audrey Hamilton, David Straus, Steven M. Horwitz, Anita Kumar, Craig H. Moskowitz, Alison Moskowitz, Andrew D. Zelenetz, Jurgen Rademaker, Gilles Salles, Venkatraman Seshan, Heiko Schöder, Anas Younes, Dana W.Y. Tsui, Connie Lee Batlevi
Journal: Clinical Cancer Research (2021)

Activation of Bruton tyrosine kinase (BTK) and phosphatidylinositol-3-kinase (PI3K) represent parallel, synergistic pathways in lymphoma pathogenesis. As predominant PI3Kδ inhibition is a possible mechanism of tumor escape, we proposed a clinical trial of dual BTK and pan-PI3K inhibition.We conducted a single-center phase I/Ib trial combining a BTK inhibitor (ibrutinib) and a pan-PI3K inhibitor (buparlisib) in 37 patients with relapsed/refractory (R/R) B-cell lymphoma. Buparlisib and ibrutinib were administered orally, once daily in 28-day cycles until progression or unacceptable toxicity. The clinical trial is registered with clinicaltrials.gov, NCT02756247.Patients with mantle cell lymphoma (MCL) receiving the combination had a 94% overall response rate (ORR) and 33-month median progression-free survival; ORR of 31% and 20% were observed in patients with diffuse large B-cell lymphoma and follicular lymphoma, respectively. The maximum tolerated dose was ibrutinib 560 mg plus buparlisib 100 mg and the recommended phase II dose was ibrutinib 560 mg plus buparlisib 80 mg. The most common grade 3 adverse events were rash/pruritis/dermatitis (19%), diarrhea (11%), hyperglycemia (11%), and hypertension (11%). All grade mood disturbances ranging from anxiety, depression, to agitation were observed in 22% of patients. Results from serial monitoring of cell-free DNA samples corresponded to radiographic resolution of disease and tracked the emergence of mutations known to promote BTK inhibitor resistance.BTK and pan-PI3K inhibition in mantle cell lymphoma demonstrates a promising efficacy signal. Addition of BCL2 inhibitors to a BTK and pan-PI3K combination remain suitable for further development in mantle cell lymphoma.
Duration Matters: Impact of Time from Diagnosis on Symptoms in Patients with Hematologic Malignancies
Authors: Leslie Padrnos, Heidi Kosiorek, Robert M Bennett, Amylou Constance Dueck, Krisstina L. Gowin, Robyn M. Scherber, Holly L. Geyer, Jeanne Palmer, Donald Northfelt, Joseph R Mikhael, Nandita Khera, Ruben A Mesa
Journal: Blood (2017)
Lysosome‐Targeted and Fluorescence‐Turned “On” Cytotoxicity Induced by Alkaline Phosphatase‐Triggered Self‐Assembly
Authors: Chengfan Wu, Chenchen Wang, Tong Zhang, Ge Gao, Mengxing Wei, Yinglu Chen, Xiaoyan Li, Fuqiang Wang, Gaolin Liang
Journal: Advanced Healthcare Materials (2021)

Selectively inducing lysosomal membrane permeabilization (LMP) is a promising strategy for cancer therapy. But integrating alkaline phosphatase (ALP)-instructed self-assembly and lysosome-targeting to induce LMP for selective killing of cancer cells was not reported. Herein, a pyrene-peptide conjugate Py-Phe-Phe-Glu-Tyr(H2 PO3 )-Gly-lyso (Py-Yp-Lyso) is rationally designed and demonstrated for its lysosome-targeting cytotoxicity on cancer cells, together with its pyrene (Py) excimer fluorescence turning "on" at 480 nm. In vitro results showed that, Py-Yp-Lyso is efficiently dephosphorylated by ALP to yield Py-Phe-Phe-Glu-Tyr-Gly-lyso (Py-Y-Lyso) which self-assembles into nanofibers. Cell experiments verified that, after being taken up by HeLa cells, the excimer fluorescence of Py-Yp-Lyso assemblies has turned "on" and the assemblies specifically target the lysosomes, inducing LMP and ultimate cancer cell death. In vivo experiments indicated that Py-Yp-Lyso has the highest inhibition effect on HeLa tumors among the four compounds studied. This is anticipated for applying Py-Yp-Lyso to treat cancers in the clinic in the future.
LBA33 Maintenance olaparib rechallenge in patients (pts) with ovarian carcinoma (OC) previously treated with a PARP inhibitor (PARPi): Phase IIIb OReO/ENGOT Ov-38 trial
Authors: E. Pujade-Lauraine, F. Selle, G. Scambia, B. Asselain, F. Marmé, K. Lindemann, N. Colombo, R. Madry, R.M. Glasspool, C. Dubot, A. Oaknin, C. Zamagni, F. Heitz, L. Gladieff, M.J. Rubio-Pérez, P. Scollo, C. Blakeley, B. Shaw, I.L. Ray-Coquard, A. Redondo
Journal: Annals of Oncology (2021)